1. A novel haemocytometric COVID-19 prognostic score developed and validated in an observational multicentre European hospital-based study.
- Author
-
Linssen J, Ermens A, Berrevoets M, Seghezzi M, Previtali G, van der Sar-van der Brugge S, Russcher H, Verbon A, Gillis J, Riedl J, de Jongh E, Saker J, Münster M, Munnix IC, Dofferhof A, Scharnhorst V, Ammerlaan H, Deiteren K, Bakker SJ, Van Pelt LJ, Kluiters-de Hingh Y, Leers MP, and van der Ven AJ
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Blood Cell Count instrumentation, Blood Cell Count methods, COVID-19 epidemiology, COVID-19 virology, Cohort Studies, Europe, Female, Humans, Male, Middle Aged, Pandemics, Prognosis, Retrospective Studies, SARS-CoV-2 physiology, Young Adult, Blood Cell Count statistics & numerical data, COVID-19 blood, Hospitalization statistics & numerical data, Hospitals
- Abstract
COVID-19 induces haemocytometric changes. Complete blood count changes, including new cell activation parameters, from 982 confirmed COVID-19 adult patients from 11 European hospitals were retrospectively analysed for distinctive patterns based on age, gender, clinical severity, symptom duration, and hospital days. The observed haemocytometric patterns formed the basis to develop a multi-haemocytometric-parameter prognostic score to predict, during the first three days after presentation, which patients will recover without ventilation or deteriorate within a two-week timeframe, needing intensive care or with fatal outcome. The prognostic score, with ROC curve AUC at baseline of 0.753 (95% CI 0.723-0.781) increasing to 0.875 (95% CI 0.806-0.926) on day 3, was superior to any individual parameter at distinguishing between clinical severity. Findings were confirmed in a validation cohort. Aim is that the score and haemocytometry results are simultaneously provided by analyser software, enabling wide applicability of the score as haemocytometry is commonly requested in COVID-19 patients., Competing Interests: JL, JS, MM is a permanent employee of Sysmex Europe GMBH who provided free of charge study reagents to the study centres. AE, MB, MS, GP, Sv, HR, AV, JG, JR, Ed, IM, AD, VS, HA, KD, SB, LV, YK, ML No competing interests declared, Av has an ad hoc consultancy agreement with Sysmex Europe GMBH who provided free of charge study reagents to the study centres., (© 2020, Linssen et al.)
- Published
- 2020
- Full Text
- View/download PDF